Miklossy et al., 2015 - Google Patents

Hirsutinolide series inhibit Stat3 activity, alter GCN1, MAP1B, Hsp105, G6PD, vimentin, TrxR1, and importin α-2 expression, and induce antitumor effects against …

Miklossy et al., 2015

View HTML
Document ID
10754114290189573277
Author
Miklossy G
Youn U
Yue P
Zhang M
Chen C
Hilliard T
Paladino D
Li Y
Choi J
Sarkaria J
Kawakami J
Wongwiwatthananukit S
Chen Y
Sun D
Chang L
Turkson J
Publication year
Publication venue
Journal of medicinal chemistry

External Links

Snippet

We report that hirsutinolide series, 6, 7, 10, 11, 20, and 22, and the semisynthetic analogues, 30, 31, 33, and 36, inhibit constitutively active signal transducer and activator of transcription (Stat) 3 and malignant glioma phenotype. A position 13 lipophilic ester group is required for …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Similar Documents

Publication Publication Date Title
Miklossy et al. Hirsutinolide series inhibit Stat3 activity, alter GCN1, MAP1B, Hsp105, G6PD, vimentin, TrxR1, and importin α-2 expression, and induce antitumor effects against human glioma
Awale et al. Ancistrolikokine E3, a 5, 8′-coupled naphthylisoquinoline alkaloid, eliminates the tolerance of cancer cells to nutrition starvation by inhibition of the Akt/mTOR/autophagy signaling pathway
Chakraborti et al. Curcumin recognizes a unique binding site of tubulin
Gibault et al. Targeting transcriptional enhanced associate domains (TEADs) miniperspective
Ai et al. Synthesis of CDDO–amino acid–nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer
EP3182129B1 (en) Method of screening a therapeutic agent for k-ras mutant cancer
Kim et al. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling
CN105120854B (en) New salicyclic acid derivatives, its pharmaceutically acceptable salt, its composition and its application method
Yu et al. Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking
Karmakar et al. Platinum (IV)-estramustine multiaction prodrugs are effective antiproliferative agents against prostate cancer cells
Tikhomirov et al. Synthesis and characterization of 4, 11-diaminoanthra [2, 3-b] furan-5, 10-diones: tumor cell apoptosis through tNOX-modulated NAD+/NADH ratio and SIRT1
Weidner et al. Amorfrutin C induces apoptosis and inhibits proliferation in colon cancer cells through targeting mitochondria
AU2014101470A4 (en) Method of using neferine for inducing cell death in apoptosis resistant cells through activation of ryanodine receptor and for treating apoptosis resistant cancer
Chen et al. Discovery of novel potent covalent glutathione peroxidase 4 inhibitors as highly selective ferroptosis inducers for the treatment of triple-negative breast cancer
Tarazona et al. Cytotoxic anomoian B and aplyzanzine B, new bromotyrosine alkaloids from Indonesian sponges
Wang et al. The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells
Tan et al. Synthesis and evaluation of bisbenzylidenedioxotetrahydrothiopranones as activators of endoplasmic reticulum (ER) stress signaling pathways and apoptotic cell death in acute promyelocytic leukemic cells
Zhong et al. Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors
Lai et al. 3′-Hydroxypterostilbene suppresses colitis-associated tumorigenesis by inhibition of IL-6/STAT3 signaling in mice
Byun et al. Design, synthesis, and biological activity of marinacarboline analogues as STAT3 pathway inhibitors for docetaxel-resistant triple-negative breast cancer
Trapella et al. Design, synthesis, and biological characterization of novel mitochondria targeted dichloroacetate-loaded compounds with antileukemic activity
Wang et al. Novel 1, 4‑naphthoquinone derivatives induce reactive oxygen species‑mediated apoptosis in liver cancer cells
Bachmann et al. Targeting mitochondrial ion channels to fight cancer
Yu et al. LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK–eIF2α–ATF4–CHOP axis
Zhang et al. Thermal Proteome Profiling Strategy Identifies CNPY3 as a Cellular Target of Gambogic Acid for Inducing Prostate Cancer Pyroptosis